FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

10 results

ayvakit
(avapritinib)
Blueprint Medicines Corporation
Usage: AYVAKIT® is indicated for adults with unresectable or metastatic gastrointestinal stromal tumors (GIST) with PDGFRA exon 18 mutations, advanced systemic mastocytosis (AdvSM), and indolent systemic mastocytosis (ISM). It is not recommended for patients with platelet counts below 50 × 10⁹/L.
imatinib mesylate
(IMATINIB MESYLATE)
Camber Pharmaceuticals, Inc.
Usage: This drug is indicated for the treatment of newly diagnosed Philadelphia positive chronic myeloid leukemia (Ph+ CML), blast crisis, and acute lymphoblastic leukemia (ALL) in adults and pediatrics, as well as for myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors.
imatinib mesylate
(Imatinib Mesylate)
Chartwell RX, LLC
Usage: This drug is indicated for treatment of Philadelphia positive chronic myeloid leukemia (CML) in various phases, acute lymphoblastic leukemia (ALL), myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, chronic eosinophilic leukemia, dermatofibrosarcoma protuberans, and Kit+ gastrointestinal stromal tumors (GIST).
imatinib mesylate
(Imatinib Mesylate)
Apotex Corp
Usage: This drug is indicated for the treatment of newly diagnosed and resistant Philadelphia chromosome positive chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), various myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastro-intestinal stromal tumors (GIST).
imatinib mesylate
(Imatinib Mesylate)
BluePoint Laboratories
Usage: This drug is indicated for newly diagnosed or treatment-resistant Philadelphia chromosome positive chronic myeloid leukemia, acute lymphoblastic leukemia in adults and pediatrics, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors in adults.
imatinib mesylate
(imatinib mesylate)
Archis Pharma LLC
Usage: This drug is indicated for the treatment of newly diagnosed Philadelphia positive chronic myeloid leukemia (Ph+ CML), Ph+ CML in various stages post-interferon therapy, relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL), myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and Kit+ gastrointestinal stromal tumors.
imatinib mesylate
(imatinib mesylate)
Qilu Pharmaceutical Co., Ltd.
Usage: This drug is indicated for treating newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), and various myelodysplastic/myeloproliferative diseases, among other conditions, including aggressive systemic mastocytosis and gastrointestinal stromal tumors.
imatinib mesylate
(imatinib)
Mylan Pharmaceuticals Inc.
Usage: This drug is indicated for the treatment of various conditions including newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (CML), Ph+ acute lymphoblastic leukemia (ALL), myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and Kit+ gastrointestinal stromal tumors (GIST).
qinlock
(Ripretinib)
Deciphera Pharmaceuticals, LLC
Usage: QINLOCK is indicated for adult patients with advanced gastrointestinal stromal tumor (GIST) who have previously been treated with three or more kinase inhibitors, including imatinib.
sutent
(Sunitinib malate)
U.S. Pharmaceuticals
Usage: SUTENT is indicated for adult patients with gastrointestinal stromal tumor (GIST) post-imatinib treatment, advanced renal cell carcinoma (RCC), adjuvant therapy for high-risk recurrent RCC post-nephrectomy, and progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in unresectable or metastatic stages.

Medications for Gastrointestinal Stromal Tumors

ayvakit

imatinib mesylate

imatinib mesylate

imatinib mesylate

imatinib mesylate

imatinib mesylate

imatinib mesylate

imatinib mesylate

qinlock

sutent